. 2022 Dec 2;19(23):16158. doi: 10.3390/ijerph192316158

Table 3.

Hematological biomarkers in the intervention group (IG n = 15) and in the control group (CG n = 15), in the three moments of the study.

Parameter (Reference Value)	Group	Time			p₁-Value	p₂-Value
Parameter (Reference Value)	Group	T1	T2	T3	p₁-Value	p₂-Value
White Blood Cells ∗10³/µL (3.8–11)	IG	4.71 ± 0.97	4.68 ± 0.97	4.61 ± 1.04	0.774	0.187
White Blood Cells ∗10³/µL (3.8–11)	CG	4.90 ± 1.50	5.0 ± 1.46	4.76± 1.34	0.235	0.187
Monocytes (%) (2.5–10)	IG	6.72 ± 1.01	6.46 ± 1.21	6.47 ± 1.21	0.136	0.197
Monocytes (%) (2.5–10)	CG	6.56 ± 1.67	6.44 ± 1. 13	6.54 ± 2.21	0.409	0.197
Lymphocytes (%) (20–51)	IG	30.11 ± 6.14	30.31 ± 9.06	31.01 ± 6. 61	0.104	0.097
Lymphocytes (%) (20–51)	CG	30.51 ± 7.60	30.35 ± 7.05	31.98 ± 5.91	0.401	0.097
Red Blood Cells ∗10⁶ mL⁻¹ (4.5–5.7)	IG	5.23 ± 0.13	5.26 ± 0.34	5.28 ± 0.21	0.314	0.188
Red Blood Cells ∗10⁶ mL⁻¹ (4.5–5.7)	CG	5.17 ± 0.60	5.16 ± 0.49	5.18 ± 0.32	0.219	0.188
Hemoglobin g∗dL⁻¹ (13–17)	IG	15.21 ± 1.11	15.23 ± 0.74	15.19 ± 0.65	0.975	0.147
Hemoglobin g∗dL⁻¹ (13–17)	CG	15.43 ± 0.71	15.46 ± 0.75	15.47 ± 1.93	0.892	0.147
Hematocrit % (40–50)	IG	44.17 ± 3.79	46.00 ± 3.83	46.14 ± 3.62	0.204	0.165
Hematocrit % (40–50)	CG	45.01 ± 2.46	45.78 ± 2.65	45.61 ± 2.591	0. 127	0.165

Data are expressed as mean ± standard deviation. p₁: analysis of variance (ANOVA) with repeated measures for each group separately. p₂: analysis of variance (ANOVA) with repeated measures of two factors to verify the existence of an interaction effect (Condition × Time). Significant differences were considered for p < 0.05. Significant differences during the study period, calculated using the Scheffé test. IG: intervention group; CG: control group; T1: baseline; T2: day 21; T3: day 42.